Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 09 tags : Phase 3 save search
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial
Published: 2021-12-09 (Crawled : 22:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics opioid positive results phase 3 topline
Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) CongressSuber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
OTLK P | $8.15 -1.69% -1.72% 270K
|
Health Technology
|
| O: 6.0%
H: 1.57%
C: -6.29%
trial therapeutics retina phase 3
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
Published: 2021-12-09 (Crawled : 19:00) - biospace.com/
CYDY | $0.1509 0.06% 810K
|
Manufacturing
|
| O: 3.81%
H: 3.67%
C: -5.5%
covid-19 fda trial covid phase 3
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics potential opioid positive therapy results phase 3 topline
IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
IOBT | $1.47 0.0% 92K
|
|
| O: -2.3%
H: 0.95%
C: 0.0%
trial trial results phase 1 results biotech iot phase 2 phase 3
ILLUMINATE-B Phase 3 Results of OXLUMO® (lumasiran) Published in Genetics in Medicine
Published: 2021-12-09 (Crawled : 15:30) - alnylam.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.29%
H: 0.31%
C: -2.8%
oxlumo genetic results phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.